Manash Pratim Pathak

Manash Pratim Pathak

Auto-generated profile, based on publicly available information

Manash Pratim Pathak

Faculty of Pharmaceutical Science, Assam down town University, Panikhaiti, Guwahati, India

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MPManash Pratim Pathak
Manash Pratim Pathak
KPKalyani Pathak
Kalyani Pathak
RSRiya Saikia
Riya Saikia
UGUrvashee Gogoi
Urvashee Gogoi
MAMohammad Zaki Ahmad
Mohammad Zaki Ahmad
ADAparoop Das
Aparoop Das
Despite enormous development in the field of drug development, cancer still remains elusive. Compromised immunity stands as a roadblock to the successful pharmacological execution of anti-cancer drugs used clinically currently. Recently some breakthrough cancer treatment strategy like nano-formulation, extracellular vesicles treatment, natural antioxidant therapy, targeted immunotherapy, gene therapy, thermal ablation and magnetic hyperthermia, and pathomics and radiomics has been developed and tested pre-clinically as well as clinically. However, clinical efficacy of such therapies is yet to establish and some are too costly to be utilized by patients from poor and developing countries. At this juncture, researchers are heading towards the search of medicines from natural sources that is higher safety margin and multitarget pharmacological efficacy compared to conventional treatments. Mushroom is used traditionally as food as well as drug since time immemorial due to its immunomodulatory effect which is loaded with proteins, low fat content and cholesterol. Mushrooms are recommended as one of the best vegetarian diets for immunosuppressed cancer and HIV/AIDS patients. Mushrooms are well-known for their anti-cancer activity that impacts hematopoietic stem cells, lymphocytes, macrophages, T cells, dendritic cells (DCs), and natural killer (NK) cells in the immune system. This comprehensive review article emphasizes on the molecular mechanisms of cancer genesis, conventional anti-cancer therapy as well as reported some significant breakthrough in anti-cancer drug development, anti-cancer activity of some selected species of mushrooms and their bioactive phytoconstituents followed by a brief discussion of recent anti-cancer efficacy of some metallic nanoparticles loaded with mushrooms.

21 May 2013 in International Journal of Toxicology
Verified
Journal Article
Closed access
SBSubham Banerjee
Subham Banerjee
PCPronobesh Chattopadhyay
Pronobesh Chattopadhyay
AGAnimesh Ghosh
Animesh Ghosh
MPManash Pratim Pathak
Manash Pratim Pathak
SSShweta Singh
Shweta Singh
VVVijay Veer
Vijay Veer
The skin irritating, sensitizing, and acute dermal toxicity potential of a novel combinational prophylactic transdermal patch, mainly composed of eserine and pralidoxime chloride as active pharmaceutical ingredients, against (±) anatoxin-a poisoning were investigated in rabbits, guinea pigs, and rats in compliance with the Organisation for Economic Cooperation and Development guidelines. In primary skin irritation test, rabbits were dermally attached with the therapeutically active transdermal patch or with a placebo patch for 72 hours. The transdermal patches did not induce any adverse reactions such as erythema and edema on intact skin sites. The active patch was classified as a practically nonirritating material based on the score in the primary irritation index. In the Buehler test, guinea pigs were sensitized by the active or placebo transdermal patches attached for 24 hours. The patches did not induce any sensitization reactions in contrast to a severe sensitization reaction that occurred in the positive control. Therefore, the active patch and placebo patch were both graded as weak in sensitization score and rate. Acute dermal toxicity test in rats did not produce any overt signs of toxicity following a 14-day treatment period. Taken together, these findings suggest that the transdermal patch does not cause skin irritation, skin sensitization, or dermal toxic effects following dermal application.

1 December 2017 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
ABAnandita Basu
Anandita Basu
Anindhya Sundar DasAnindhya Sundar Das
Anindhya Sundar Das
MSManoj Sharma
Manoj Sharma
MPManash Pratim Pathak
Manash Pratim Pathak
PCPronobesh Chattopadhyay
Pronobesh Chattopadhyay
RMRupak Mukhopadhyay
Rupak Mukhopadhyay
Cycloxygenase-2 (COX-2) is the inducible isoform of cycloxygenase enzyme family that catalyzes synthesis of inflammatory mediators, prostanoids and prostaglandins, and therefore, can be targeted by anti-inflammatory drugs. Here, we showed a plant polyphenol, kaempferol, attenuated IL-6-induced COX-2 expression in human monocytic THP-1 cells suggesting its beneficial role in chronic inflammation. Kaempferol deactivated and prevented nuclear localization of two major transcription factors STAT3 and NF-κB, mutually responsible for COX-2 induction in response to IL-6. Moreover, STAT3 and NF-κB were simultaneously deactivated by kaempferol in acute inflammation, as shown by carrageenan-induced mouse paw edema model. The concomitant reduction in COX-2 expression in paw tissues suggested kaempferol's role in mitigation of inflammation by targeting STAT3 and NF-κB.


30 September 2022 in Journal of Pharmacopuncture
Verified
Journal Article
Open access
PDF file
PBPervej Alom Barbhuiya
Pervej Alom Barbhuiya
ALAbdul Mannaf Laskar
Abdul Mannaf Laskar
HMHemanga Mazumdar
Hemanga Mazumdar
PDPartha Pratim Dutta
Partha Pratim Dutta
MPManash Pratim Pathak
Manash Pratim Pathak
SSSaikat Sen
Saikat Sen
Pervej Alom Barbhuiya, Abdul Mannaf Laskar, Hemanga Mazumdar, Partha Pratim Dutta, Manash Pratim Pathak, Biplab Kumar Dey, Saikat Sen. J Pharmacopuncture 2022;25:149-85. https://doi.org/10.3831/KPI.2022.25.3.149

10 April 2023 in Heliyon
Verified
Journal Article
Open access
MPManash Pratim Pathak
Manash Pratim Pathak
kalyani pathakkalyani pathak
kalyani pathak
RSRiya Saikia
Riya Saikia
UGUrvashee Gogoi
Urvashee Gogoi
PPPompy Patowary
Pompy Patowary
ADAparoop Das
Aparoop Das
Nonalcoholic fatty liver disease (NAFLD), a chronic liver condition affects a large number of people around the world with a frequency of 25% of all the chronic liver disease worldwide. Several targets viz. anti-inflammatory, anti-apoptotic and, anti-fibrotic factors, anti-oxidant and insulin-sensitizing pathways, metabolic regulators as well as repurposing traditional medications have been studied for the pharmacologic therapy of NAFLD. Newer pharmacotherapies like caspases blockade, agonists of PPAR and farnesoid X receptor agonists are currently being investigated in treating human NAFLD. However, NAFLD has no FDA-approved pharmacological therapy, therefore there is a considerable unmet therapy need. Apart from the conventional treatment regime, the current approaches to treating NAFLD include lifestyle interventions including healthy diet with adequate nutrition and physical activity. Fruits are known to play a key role in the well-being of human health. Fruits are loaded with a repertoire of bioactive phytoconstituents like catechins, phytosterols, proanthocyanidin, genestin, daidzen, resveratrol, magiferin found in fruits like pear, apricot, strawberries, oranges, apples, bananas, grapes, kiwi, pineapple, watermelon, peach, grape seed and skin, mango, currants, raisins, dried dates, passion fruit and many more. These bioactive phytoconstituents are reported to demonstrate promising pharmacological efficacy like reduction in fatty acid deposition, increased lipid metabolism, modulation of insulin signaling pathway, gut microbiota and hepatic inflammation, inhibition of histone acetyltransferase enzymatic activity to name a few. Not only fruits, but their derivatives like oils, pulp, peel, or their preparations are also found to be equally beneficial in various liver diseases like NAFLD, NASH. Although most of the fruits contains potent bioactive phytoconstituents, however, the presence of sugar in fruits put a question mark on the ameliorative property of the fruits and there has been contrasting reports on the glycemic control post fruit consumption in type 2 diabetic patients. This review is an attempt to summarize the beneficial effects of fruit phytoconstituents on NAFLD based on epidemiological, clinical and experimental evidence, focusing especially on their mechanisms of action.